logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Mid 2016
BIODEL INC
Top line results from phase 2b trial of BIOD-531
Insulin-treated type 2 diabetes
Mid 2016
RedHill Biopharma Ltd.
Top-line data Phase 3 study of Bekinda (GUARD study)
Acute gastroenteritis and gastritis
Mid 2016
GW Pharmaceuticals PLC
GWPH, GWP.L
Data from phase 1b/2a study of GWP42002:GWP42003
Recurrent Glioblastoma Multiforme
Mid 2016
Dermira Inc.
Topline data from phase 3 study of DRM04i
Hyperhidrosis
Mid 2016
Ultragenyx Pharmaceutical Inc
Safety and efficacy data from Phase 3 trial of rhGUS
Mucopolysaccharidosis 7 (MPS 7)
Mid 2016
Marinus Pharmaceuticals
Topline data from phase 3 study of Ganaxolone Capsule
Refractory Focal Onset Seizures:
Mid 2016
Marinus Pharmaceuticals
Full data from Phase 2 trial for PCDH19
Female Pediatric Epilepsy
Mid 2016
Rigel Pharmaceuticals Inc.
Topline data from 1st phase 3 trial of Fostamatinib
Immune thrombocytopenic purpura
Mid 2016
Vertex Pharmaceuticals Inc.
Results from phase 2a study of inhaled VX-371
Cystic fibrosis
Mid 2016
Esperion Therapeutics
Topline data from phase II study of Bempedoic acid
Lowering LDL cholesterol
Q2 2016
Sophiris Bio Inc.
Final data from phase Phase 2a proof of concept study of PRX302
Prostate cancer
Q2 2016
Oramed Pharmaceuticals Inc.
ORMP, ORMP.OB
Topline data from phase IIb trial of ORMD-0801
Type 2 Diabetes
Q2 2016
ProNAi Therapeutics Inc
Initial data from Phase 2 monotherapy trial of PNT2258 ( Wolverine)
Relapsed or refractory diffuse large B-cell lymphoma,
Q2 2016
Prothena Corporation plc
Topline results from expansion cohort of a phase 1/2 study of NEOD001
AL amyloidosis
Q2 2016
TESARO, Inc.
Topline data from Phase 3 trial of Niraparib (NOVA)
Ovarian cancer
Q2 2016
TESARO, Inc.
Report topline data from phase 2 trial of Niraparib (QUADRA)
Ovarian cancer
Q2 2016
Trevena, Inc.
Top-line data from phase 2b trial of TRV027 (BLAST-AHF )
Acute Heart Failure
Q2 2016
Minerva Neurosciences Inc
Topline results from phase IIb study of MIN-101
Improving negative symptoms of schizophrenia.
Q2 2016
Dermira Inc.
Topline results from phase 2b trial DRM01
Acne
Q2 2016
Innocoll AG
Topline results from 1st & 2nd phase 3 trials of XaraColl (MATRIX-1 & MATRIX-2)
Postoperative pain
Q2 2016
Affimed N.V.
Final data from phase 2a trial of AFM13
Hodgkin lymphoma
01-Mar-2016 To 30-Apr-2016
Biomarin Pharmaceutical Inc.
Topline results from Phase 3 trial with PEG PAL
Phenylketonuria
Feb 2016
Flexion Therapeutics, Inc.
Topline data from phase 3 trial of Zilretta
Osteoarthritis knee pain
Q1 2016
Aldeyra Therapeutics, Inc.
Data from phase II trial of NS2
Allergic conjunctivitis
Q1 2016
Alkermes plc
Data from phase 3 trial of ALKS 5461 (FORWARD-3 and FORWARD-4)
Major depressive disorder